Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine the progression-free survival (PFS) rate assessed 12 weeks after the initiation of IMC-A12 monotherapy, administered every 2 weeks to patients with previously-treated, advanced or metastatic soft tissue and Ewing’s sarcoma/PNET.
Critère d'inclusion
- Sarcoma de tejido blando y sarcoma de Ewing/Tumor neuroectodérmico periférico primitivo (TNEPP) tratado anteriormente, avanzado o metastásico,Previously-treated, advanced or metastatic soft tissue and Ewing’s sarcoma/peripheral primitive neuroectodermal tumor (PNET)